About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, June 24th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

CRAiLAR Technologies, Inc. (CRLRF)

FeedBlitz reported recently on reported this month on CRAiLAR Technologies, Inc. (CRLRF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

CRAiLAR Technologies, Inc. offers cost-effective and environmentally sustainable natural fiber in the form of flax, hemp and other bast fibers. These are for use in textile, industrial, energy, medical and composite material applications. The OTC BB listed Company established in 1998 as a provider of environmentally friendly, socially responsible clothing. CRAiLAR Technologies has their corporate headquarters in Victoria, British Columbia. They have their U.S. office in Lake Oswego, Oregon, and a production facility in Pamplico, South Carolina.

CRAiLAR was originally a provider of the aforementioned environmentally friendly, ethically produced clothing. They grew quickly via strategic partnerships with Canada’s National Research Council and Alberta Innovates-Technologies Futures to become a leading developer of renewable and environmentally sustainable biomass resources.

CRAiLAR Technologies supplies their CRAiLAR Flax to HanesBrands, Georgia-Pacific, Brilliant Global Knitwear, Tuscarora Yarns, Target Corp. and Kowa Company for commercial use. They supply it to Levi Strauss & Co., Cintas, Carhartt, Ashland, PVH Corp., Cotswold Industries, Cone Mills, as well as Lenzing for evaluation and development.

CRAiLAR Flax is the newest natural fiber introduction to the market in decades. The production of this product is through using a fraction of water and chemical inputs in comparison with other natural fibers. The USDA has designated CRAiLAR Flax Fiber 100 percent BioPreferred®. Flax is among the oldest textile crops in recorded history.

In May, CRAiLAR Technologies announced that the Company has joined the Sustainable Apparel Coalition (SAC). They will use this group's sustainability measurement tool, the Higg Index, to measure environmental responsibility across the company’s agriculture and manufacturing processes.

In their relationship with the SAC, CRAiLAR will contribute data and resources to support the Higg Index. The Higg Index measures environmental sustainability and drives supply chain decision-making to better efficiency and sustainability impact. Currently, there are over 90 members of the SAC. The majority are global brands and retailers.

CRAiLAR Technologies, Inc. (CRLRF), closed Monday’s trading session at $1.0369, up 4.74%, on 7,020 volume with 5 trades. The average volume for the last 60 days is 40,000 and the stock's 52-week low/high is $0.963/$2.7534.

Limitless Venture Group, Inc. (LVGI)

Today we are highlighting Limitless Venture Group, Inc. (LVGI), here at the QualityStocks Daily Newsletter.

Limitless Venture Group, Inc. is a full service brand development company whose shares trade on the OTC Pink Current Information. The Company has an in house Bio-Chemical engineering and formulations department, an in-house brand identity team, a full graphics department and an experienced group of marketing professionals. Limitless Venture Group, based in Holbrook, New York, specializes in beverage, supplement and healthy lifestyle products.

The Company and their group of diversified wholly owned subsidiaries have four product lines that are market ready. Through their Limitless Body, Inc. subsidiary they have their Limitless Body and their Limitless Health product lines. These are fully developed, tested, and ready for full production. The Company’s Genetically Enhanced Anabolic Research, Inc. (G.E.A.R.) subsidiary has a full line of sports supplements developed, tested and ready for full production.

Additionally, Limitless controls - as a 100 percent wholly owned subsidiary - Limitless Brands, Inc. Limitless Brands serves as their alcoholic brand division. SLAM Infusination is the Company’s line of RTD (Ready to Drink) alcoholic shots. The marketing of these is targeted at the nearly untapped grab-and-go counter item space of the huge alcohol industry. SLAM has it owns formulation, graphics and marketing departments; it has complete federal and state approvals and is market ready.

Today, Limitless Venture Group announced, via their G.E.A.R sports neutraceuticals subsidiary, the introduction of their unique Shock Series product line with patent-pending BEET DRIVE Technology. The initial workout line of supplements will consist of three products that focus on timing windows for maximum work out performance, sustentation, as well as recovery.

G Shock is their flagship pre-workout product. It will be accompanied by E Shock, the intra-workout and endurance enhancer, and Maxx Shock post workout supplement, which concentrates on muscle recovery. The Shock Series has no artificial sweeteners, colors or preservatives. The Shock Series will be available to consumers this fall.

Limitless Venture Group, Inc. (LVGI), closed Monday’s trading session at $0.099, down 23.85%, on 3,312,240 volume with 400 trades. The average volume for the last 60 days is 51,016 and the stock's 52-week low/high is $0.05/$2.10.

Decision Diagnostics Corp. (DECN)

Stockoutlaws, Investor Ideas, Investor Stock Alerts, and OTCPicks reported earlier on Decision Diagnostics Corp. (DECN), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Decision Diagnostics Corp. is developing products that offer innovative solutions in medical care and management through providing physicians with essential information at the point of care. The Company is a foremost provider of prescription drugs, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of innovative cell phone centric e-health products and technologies.

The Company previously went by the name InstaCare Corp. They changed their name to Decision Diagnostics Corp. in November of 2011. Founded in 2000, the Company has their headquarters in Westlake Village, California. Decision Diagnostics’ shares trade on the OTC Markets’ OTCQB.

The Company uses smart phones, which allow physicians to carry, access and update their patients' histories, medication data, and best care guidelines, all at the point of care. Decision Diagnostics’ products include glucose monitoring systems, wound care and ostomy products, and the Shasta GenStrip. The Shasta Genstrip is for at-home testing of blood glucose. The Shasta Genstrip fits into a diagnostic product niche and is for the global self-test (home test) market.

The Company additionally offers information technology solutions in several medical care market channels. Their products make use of smart cell phones and a wide array of Microsoft Windows based smart phones and operates in a wireless or "wired" mode.

Decision Diagnostics offers ResidenceWare. This is a collection of Internet-enhanced communication, integration, and networking tools developed for the real estate marketplace. They also offer MD@Hand. This is a smartphone application that takes advantage of the connectivity of handheld devices via the Internet. The Company’s technologies manage critical data and e-commerce, and facilitate communication with applications in the healthcare, apartment, and hotel/motel industries.

Decision Diagnostics also has their Practice Probe. The work of Practice Probe is as a data mining utility used to extract information from the physician's Practice Management System and to utilize that information in MD@Hand.

Decision Diagnostics Corp. (DECN), closed Monday at $0.24, up 11.63%, on 35,612 volume with 14 trades. The average volume for the last 60 days is 44,703 and the stock's 52-week low/high is $0.052/$0.40.

Elite Pharmaceuticals, Inc. (ELTP)

OTCBB Journal, First Penny Picks, and Real Pennies reported earlier on Elite Pharmaceuticals, Inc. (ELTP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company with headquarters in Northvale, New Jersey. The Company’s dedication is to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals. Elite has five commercial products presently selling, an additional product approved and soon to be launched, and one additional product under review pending approval by the U.S. Food and Drug Administration (FDA).

The Company’s lead pipeline products include abuse resistant opioids utilizing Elite’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain. They address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

In addition, Elite Pharmaceuticals provides contract manufacturing for Mikah Pharma and Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Moreover, they have partnered with: Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the U.S. market and their territories.

This month, Elite Laboratories, a wholly owned subsidiary of Elite Pharmaceuticals, announced that the Company submitted a Citizen Petition to the FDA requesting that the FDA make a determination that (a) it is suitable to use the currently approved and marketed ANDA product (ANDA 078648, generic to Drixoral brand) as the Reference Listed Drug (RLD) since the current RLD Drixoral brand is no longer available in the marketplace, and (b) that this currently approved and marketed ANDA product is suitable to use as a RLD for an equivalent active ingredient comprised of a difference salt.

Last Friday, Elite Pharmaceuticals announced results for the fiscal year ended March 31, 2013. Consolidated revenues were $3.4 million for the fiscal year. This represents an increase of $1.0 million or approximately 40 percent over consolidated revenues for the prior year. Revenues for the quarter ended March 31, 2013 totaled $1.5 million. This is the highest quarterly revenue level in corporate history; it is 131 percent above quarterly revenues for the comparable period of the prior year.

Consolidated loss from operations was $1.6 million, and GAAP net income, including non-cash income relating to the accounting treatment of preferred share and warrant derivatives was $1.5 million. Basic earnings per share were $0.00 on a weighted average 349.1 million common shares outstanding. Fully diluted loss per share was $(0.00), on a weighted average of 526.9 million shares outstanding on a fully diluted basis.

Elite Pharmaceuticals, Inc. (ELTP), closed Monday’s session at $0.08, up 3.90%, on 6,716,187 volume with 275 trades. The average volume for the last 60 days is 1,004,460 and the stock's 52-week low/high is $0.0507/$0.143.

Lamperd Less Lethal, Inc. (LLLI)

Today we are reporting on Lamperd Less Lethal, Inc. (LLLI), here at the QualityStocks Daily Newsletter.

Listed on the OTC Pink Current Information, Lamperd Less Lethal, Inc. is a manufacturer of law enforcement products. Headquartered in Sarnia, Ontario, the Company designs and manufactures specialty civil defense equipment. In addition, they provide all-inclusive training to diverse groups of Public Safety Agencies around the world. Incorporated in 2001, Lamperd Less Lethal’s area of specific expertise is the Less-Lethal tactics and equipment with a special focus on munitions and launchers.

Lamperd has been assigned a NATO Commercial and Government Entity (NCAGE) Code. This enables them to sell military supplies to any NATO member country. The Company has also been assigned a federal Business Firearms License; this allows for the manufacture, repair, storage, import, export and sale of almost any manner of firearms and ammunition.

The design of Less-Lethal weaponry is to ensure the safety of military and civil defense personnel through disabling an opponent rather than killing. The Company has developed a line of premier high quality launcher systems. Their production of an array of less lethal munitions is rapidly gaining recognition for consistently high quality and superior performance. The design of munitions is for their proprietary launcher systems. However, they can additionally be utilized in weapons produced by a broad spectrum of other manufacturers.

In addition, Lamperd manufactures a state-of-the-art firearms training simulator, (Firearm Training Systems). The Company also manufactures training replicas of the popular weapons used by Law Enforcement and Military personnel.

Lamperd Less Lethal’s current product line-up includes a hand held launcher (Defender 1), a long gun version (Defender 2), and a Police and Military 50 cal. less lethal upper that converts the M4 or the AR15 rifle into less lethal in less than 30 seconds. This is to ensure a positive outcome in the most difficult situations.

Furthermore, they manufacture a range of less-lethal munitions including a sock round, which uses a small sock of lead shot. Additionally, they manufacture the WASP synthetic round, which uses a proprietary butyl rubber (patented) projectile, distractionary rounds, both powderized incapacitant rounds, as well as training rounds.

Concerning Training, Lamperd offers military, police and security training. The Company holds training courses by professional training instructors from the police and military. The Company also manufactures suits and equipment to accompany the training. These programs offer the trainees real life scenarios in a real life setting.

Lamperd Less Lethal, Inc. (LLLI), closed Monday’s trading session at $0.07, even for the day. The average volume for the last 60 days is 54,487 and the stock's 52-week low/high is $0.015/$0.07.

Terra Energy Corp. (TT.TO)

We are highlighting Terra Energy Corp. (TT:CA) today, here at the QualityStocks Daily Newsletter.

Based in Calgary, Alberta, Terra Energy Corp. is a junior exploration and production company. They engage in the exploration for, and development and production of, natural gas and oil in Western Canada. The concentration of their operations is mainly in northeastern British Columbia (B.C.) and the Peace River Arch region of Alberta. Terra Energy’s shares trade on the Toronto Stock Exchange.

The Company’s focus is on building a strong asset base via land acquisitions, seismic data interpretation, as well as exploration and development drilling. Terra Energy will pursue a program of balancing higher risk exploration programs with low risk development drilling, complemented by property and corporate acquisitions.

Their operating activities are in two segments. One segment is their conventional operations. These make up nearly all of the Company’s current production. The other segment is the Montney resource play in northeastern B.C; here, Terra Energy owns a leading land position in the unconventional Montney gas and gas liquids and the nascent unconventional Montney condensate and shale oil play.

Production from Alberta accounts for most of Terra Energy’s oil and Natural Gas Liquids (NGL) content. Less than half of the Company’s production is attributed to Alberta. Most of their current conventional production is attributed to B.C. Key producing regions in British Columbia include Stoddart, Sunrise, Boudreau, Tower and Wilder.

However, currently, there is practically no production and minimal reserves attributed to their Montney lands. Moreover, the Montney does not presently contribute in any material sense to either production or cash flow. On December 14, 2012, Terra Energy successfully completed the initial portion of the Montney sale transaction for a cash consideration of $22.0 million. On February 28, 2013, they successfully closed on an additional sale of the Montney for a cash consideration of $20.0 million.

Earlier this month, Terra Energy announced that Crew Energy, Inc. exercised the option to purchase the balance of Terra's Montney assets for a purchase price of $36 million. The two companies also entered into a fully executed purchase and sale agreement concerning this sale. Terra’s intention is to use the net proceeds from this sale to further reduce their indebtedness.

Terra Energy Corp. (TT:CA), closed Monday’s trading session at $0.28, down 1.75%, on 3,750 volume. The stock's 52-week low/high is $0.09/$0.38.

Labor SMART, Inc. (LTNC)

Zack’s, PennyStocks24, Buzz Stocks, Planet Penny Stocks, Penny Pick Finders, SecretStockPromo, PennyStockProphet, and StockOnion reported recently on Labor SMART, Inc. (LTNC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Labor SMART, Inc. provides On-Demand temporary staffing to an assortment of industries. They established to provide a reliable, dependable, and flexible resource for on-demand personnel to small and large businesses. Their goal is to become a nationwide resource and partner for their clients. Currently, Labor SMART operates 14 branch locations. Founded in 2011, the Company is based in Hiram, Georgia.

Labor SMART provides labor, daily, for jobs in construction, manufacturing, hospitality, events, restoration, warehousing, retail, disaster relief and more. For longer term staffing needs, Labor SMART screens every employee to make sure the right person is placed in the right job. Businesses can fill out an online form on the Company's website to get a free pricing quote.

The Company is one of the fastest growing temporary labor providers. Their staffing professionals help businesses meet their immediate production deadlines, staff shortages, or short-notice temporary labor requirements.

In May, Labor SMART announced that they acquired substantially all of the operating assets of Florida-based Qwik Staffing Solutions, Inc. The acquisition adds three additional branches located in Jacksonville, Orlando and Tampa, Florida. Based on historical performance; Labor SMART expects these additional branches to produce greater than $3.2 million in revenue and contribute approximately $350,000 to the Company's EBITDA over the next 12 months.

The Company's clients range from small businesses to Fortune 100 companies. Labor SMART's current locations are in Nashville and Chattanooga, Tennessee; Augusta and Marietta, Georgia; Greenville and Columbia South Carolina; Birmingham, Alabama; Orlando, Tampa, and Jacksonville, Florida; Charlotte, North Carolina; Indianapolis, Indiana; Louisville, Kentucky; and Kansas City, Missouri.

Earlier this month, Labor SMART reported record revenues of $1,578,503 for the month of May 2013. This is in comparison to revenues of $539,007 in May 2012. This represents a 192 percent increase in revenues over the same month of the prior year.
The month of May represents the third consecutive month where Labor SMART has exceeded more than one million dollars in revenues in 2013. Year-to-date revenues have shown an equally notable increase of 127 percent with $5,086,166 in 2013 versus $2,238,446 in 2012.

Labor Smart, Inc. (LTNC), closed Monday at $0.27, down 5.26%, on 24,650 volume with 6 trades. The average volume for the last 60 days is 38,392 and the stock's 52-week low/high is $0.10/$0.82.

Urologix, Inc. (ULGX)

Wall Street Resources, ChartPoppers, MadPennyStocks, StockEgg, PennyInvest, PennyStockVille, StockRich, BullRally, CoolPennyStocks, HotOTC and Stock Fortune Teller reported previously on Urologix, Inc. (ULGX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 1991, Urologix, Inc. develops, manufactures, markets as well as distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company sells their products to urologists, ambulatory surgery centers, and hospitals via their direct sales force, and distributors in the U.S. and internationally.

Urologix lists on the OTCQB; the Company has their corporate headquarters in Minneapolis, Minnesota. Urologix has two complementary technologies used for In-Office BPH Therapy: Cooled ThermoTherapy™ (CTT) and Prostiva® RF Therapy.

Urologix' Cooled ThermoTherapy™ (CTT) produces targeted microwave energy combined with an innovative cooling mechanism to protect healthy tissue (protect the urethra) and enhance patient comfort. CTT produces this targeted microwave energy to destroy prostate tissue and relieve BPH symptoms. CTT is appropriate for men experiencing moderate to severe BPH symptoms. It is especially appropriate for patients who do not want to take daily medications for the rest of their lives, dislike the side effects and continuing costs of medication, or do not want the risks, side effects or high costs of surgery.

The Prostiva® (registered trademark of Medtronic, Inc.) RF Therapy System delivers radio frequency energy directly into the prostate. This destroys prostate tissue, reduces constriction of the urethra, and consequently relieves BPH symptoms. Prostiva® provides direct visualization of the anatomy during the procedure. Prostiva® treats the median and lateral lobe as well as asymmetrical prostates. Cooled ThermoTherapy™ (CTT) and Prostiva® both provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.   

In April of this year, Urologix announced that they reached an important milestone in the Company’s licensing agreement with Medtronic for the Prostiva® RF Therapy System. Under the agreement, Urologix will become the licensed manufacturer for the Prostiva® RF Therapy System, obtaining manufacturing and regulatory responsibility for the product line.

This milestone represents a vital step in the integration of the Prostiva® product line into the broader Urologix organization. It will allow Urologix to work directly with their manufacturing partners to ensure continued focus on quality and efficiency moving ahead. Furthermore, achieving this landmark enables Urologix to market and sell all Prostiva® RF Therapy products distributed throughout the U.S. under the Urologix brand name.

Urologix, Inc. (ULGX), closed Monday’s trading session at $0.20, up 24.92%, on 114,274 volume with 20 trades. The average volume for the last 60 days is 23,599 and the stock's 52-week low/high is $0.1601/$0.40.

graphic

The QualityStocks
Company Corner

graphic
graphic

Frozen Food Gift Group Inc. (FROZ)

The QualityStocks Daily Newsletter would like to spotlight Frozen Food Gift Group Inc. (FROZ). Today, Frozen Food Gift Group Inc. closed trading at $0.0044, up 46.67%, on 21,333 volume with 3 trades. The stock’s average daily volume over the past 60 days is 161,511, and its 52-week low/high is $0.0001/$0.07.

Frozen Food Gift Group Inc. (FROZ) wholly owned subsidiary is named Miami Ice Machine.

In February 2013, Frozen Food Gift Group announced that it had purchased Miami Ice Machine Company (www.MiamiIceMachine.com) for restricted stock. Founded in 1961, Miami Ice Machine (MIMCO) is a leading provider of quality refrigeration equipment of numerous different types, including walk-in refrigerators and state-of-the-art freezers, with more than 50 years of operation. Boasting clientele ranging from nationally franchised businesses to single-location operators, the company is known for its continual innovation and leading refrigeration technologies.

Miami Ice Machine has manufactured and installed more than 100,000 pieces of equipment for its customers in a variety of industries. MIMCO recently announced a long term agreement with BioZone Scientific International to incorporate the latest-generation ice machine sanitation technologies into its complete line of ice machines. This new technology both prevents contamination by harmful bacteria and provides operators a safe and effective way to automate ice machine sanitation. BioZone Scientific’s compact device, IceZone® X, will be included as a standard feature in all new Miami Ice Machine Company machines, the very first time automated ice machine sanitation is included as a standard feature. IceZone® X dramatically reduces the ice machine cleaning cycle by approximately 75 percent, dropping significantly the maintenance burden for operators.

With a solid business model in place, a successful marketing strategy, and direct access to the best refrigeration technologies, the company is well prepared for its future. Disclaimer

Frozen Food Gift Group Inc. Blog

Frozen Food Gift Group Inc. News:

Frozen Food Gift Group Inc. Announces Partnership To Launch Groundbreaking Ice Machine Sanitation Technology

Frozen Food Gift Group Inc. Purchases Ice Machine Firm

The Aristocrat Group Corp. (ASCC)

The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $0.61, up 5.17%, on 258,403 volume with 122 trades. The stock’s average daily volume over the past 60 days is 342,310, and its 52-week low/high is $0.21/$1.25.

The Aristocrat Group Corp. announced today that, as part of the promotional push for RWB Ultra-Premium Handcrafted Vodka by Luxuria Brands, they are lining up blind taste tests to demonstrate the new product’s superior taste and flavor profile. Set to debut in August, this artisan vodka distilled from Idaho russet potatoes is gluten-free and finishes with an exceptionally smooth taste, for a much more enjoyable drinking experience and this fact will draw plenty of attention as they draw towards the product's entrance into the $21 billion U.S. spirits market.

The Aristocrat Group Corp. (ASCC) is a brand management company focused on providing premiere luxury goods through continual innovation. Luxuria Brands, a subsidiary of The Aristocrat Group, has been established to identify and promote unique brands that have mass market appeal across a diverse demographic.

Luxuria Brands is primarily concentrated on distilled spirits industries, with an initial focus on Vodka branding and marketing. The worldwide distilled spirits market is currently worth about $263 billion. In the U.S. alone, Vodka sales between 2004 and 2009 grew 25% from 13.9 million cases to 58.4 million cases. The clear liquor now accounts for almost a third of all distilled spirits consumed and continues to rise in popularity.

The Aristocrat Group is also pursuing opportunities in the women’s lifestyle industry. The World Bank recently estimated that the earning power of women will reach $18 trillion by 2014, which is twice the estimated 2014 GDP of China and India combined. The Aristocrat Group is working to bring fresh, innovative prenatal and postpartum solutions to women who are looking for a more comprehensive approach to wellness.

The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. The company aims to take a leadership position in multiple growing markets that offer opportunities for partnership, sponsorship, and brand awareness activities. The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. Disclaimer

The Aristocrat Group Corp. Company Blog

The Aristocrat Group Corp. News:

ASCC Lines Up Blind Taste Tests for Hot New Gluten-Free Vodka

ASCC Explores Potentially Lucrative Sports Sponsoring Opportunities

ASCC Begins Brand-Building Wholesale Initiative

VentriPoint Diagnostics Ltd. (VPTDF)

The QualityStocks Daily Newsletter would like to spotlight VentriPoint Diagnostics Ltd. (VPTDF). Today, VentriPoint Diagnostics Ltd. closed trading at $0.0837, even with yesterday's close. The stock’s average daily volume over the past 60 days is 20,636, and its 52-week low/high is $0.073/$0.163.

VentriPoint Diagnostics Ltd. announced completion of a first closing today of the second of its two previously announced non-brokered private placements, while also offering markets a corporate update. Among the highlights are development of a clinical trial protocol to evaluate if Ventripoint Medical System (VMS) assessment in patients admitted with congestive heart failure can predict hospital readmission within 30 days of discharge, as well as the upcoming June 29-July 2 exhibition at the 24th Scientific Sessions of the American Society of Echocardiology in Minneapolis, Minnesota discussing the clinical uses of the VMS.

VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.

VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.

The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis. Disclaimer

VentriPoint Diagnostics Ltd. Company Blog

VentriPoint Diagnostics Ltd. News:

VentriPoint Announces Closing of Private Placement and Corporate Update

Ventripoint Announces New Vice-President of Sales and Marketing

VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.036, off by 5.26%, on 895,728 volume with 39 trades. The stock’s average daily volume over the past 60 days is 2,010,850, and its 52-week low/high is $0.0275/$0.155.

Advaxis Inc. announced submission today of an Application for Orphan Drug Designation to the FDA for their lead HPV-associated anal cancer candidate, ADXS-HPV. Securing this designation is key for ADXS as it would enable clinical protocol assistance with the FDA, as well as federal grants, tax credits, and potentially a seven year market exclusivity period, which would be huge, considering that 85% of the 7,060 new cases of anal cancer projected for 2013 are caused by HPV according to the CDC's own figures.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Requests Orphan Drug Designation for Treatment of HPV-Associated Anal Cancer with ADXS-HPV

Advaxis Announces Results of 2013 Annual Meeting of Stockholders

Advaxis Requests Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer with ADXS-HPV

Frozen Food Gift Group Inc. (FROZ) is “One to Watch”

Frozen Food Gift Group’s wholly owned subsidiary is named Miami Ice Machine.

In February 2013, Frozen Food Gift Group announced that it had purchased Miami Ice Machine Company (www.MiamiIceMachine.com) for restricted stock. Founded in 1961, Miami Ice Machine (MIMCO) is a leading provider of quality refrigeration equipment of numerous different types, including walk-in refrigerators and state-of-the-art freezers, with more than 50 years of operation. Boasting clientele ranging from nationally franchised businesses to single-location operators, the company is known for its continual innovation and leading refrigeration technologies.

Miami Ice Machine has manufactured and installed more than 100,000 pieces of equipment for its customers in a variety of industries. MIMCO recently announced a long term agreement with BioZone Scientific International to incorporate the latest-generation ice machine sanitation technologies into its complete line of ice machines. This new technology both prevents contamination by harmful bacteria and provides operators a safe and effective way to automate ice machine sanitation. BioZone Scientific’s compact device, IceZone® X, will be included as a standard feature in all new Miami Ice Machine Company machines, the very first time automated ice machine sanitation is included as a standard feature. IceZone® X dramatically reduces the ice machine cleaning cycle by approximately 75 percent, dropping significantly the maintenance burden for operators.

With a solid business model in place, a successful marketing strategy, and direct access to the best refrigeration technologies, the company is well prepared for its future.

For more information, visit www.MiamiIceMachine.com

The Aristocrat Group Corp. (ASCC) to Promote Gluten-Free Vodka with Blind Taste Tests

As part of the promotional push planned for its RWB Ultra-Premium Handcrafted Vodka, the Aristocrat Group today announced it is lining up blind taste tests to demonstrate the new product’s superior taste and flavor profile.

The blind taste tests will put RWB, the company’s first ultra-premium offering slated for launch in August, in direct competition with the world’s most popular vodka brands. Distilled from Idaho russet potatoes, RWB Ultra-Premium Handcrafted Vodka has been designed to provide a smoother, more enjoyable drinking experience.

“We’re very eager to demonstrate RWB’s superiority in this booming marketplace,” said ASCC CEO Robert Federowicz. “We’re delivering the new primary choice for vodka drinkers. High-profile blind taste tests will give us the opportunity to showcase the remarkable care that went into creating this truly exceptional spirit.”

Focus group tests indicate that RWB Ultra-Premium Handcrafted Vodka will set itself apart and be the first choice for consumers. With the gluten-free products market expected to reach $6.2 billion by 2018, ASCC is well positioned for future growth in the $21 billion U.S. spirits industry.

For more information, visit www.aristocratgroupcorp.com

VentriPoint Diagnostics Ltd. (VPTDF) Releases Thick Corporate Update, Closing of $500,000 Private Placement

VentriPoint Diagnostics today provided a corporate update and said that it has completed a first closing of the second of two non-brokered private placements.

As previously reported, the U.S. FDA had requested additional information concerning the company’s 510(k) submission for Pulmonary Arterial Hypertension (“PAH”). In response, VPTDF said it has prepared a detailed statistical plan to obtain the information required in collaboration with the Hospital for Sick Children, Toronto, which will re-analyze the clinical studies.

In accordance with its original plans for the clinical trial, VPTDF has completed the collection of an additional 21 clinical cases, which along with the 54 studies used in the first analysis, yields 75 total cases. The new analysis will use all 75 cases and will take approximately six to eight weeks to complete. The PAH clinical trial has been completed.

The company also announced:

• Tetralogy of Fallot (TOF) clinical trial has finished recruitment with the 75 required clinical cases – the study is now completed and closed. The analysis of the data will begin upon completion of the PAH analysis.

• The development of a clinical trial protocol in collaboration with a major cardiac center interested in evaluating if VMS assessment of right heart function and structure in patients admitted with congestive heart failure can predict hospital readmission within 30 days of discharge (see CEO blog on Web site http://ventripoint.com/index.php?Itemid=511).

• The company last week exhibited at the 11th International Symposium entitled “Echocardiography Today and Tomorrow” in St. Wolfgang, Austria.

• From June 29-July 2, 2013, VPTDF will exhibit at the 24th Scientific Sessions of the American Society of Echocardiology (“ASE”) in Minneapolis, Minnesota. There will be three scientific papers presented by three groups of researchers discussing the clinical use of the VMS.

• A multicentre group from the University of Chicago and Elisabethinen Hospital in Linz, Austria will present a study entitled “Three-dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction in Pulmonary Arterial Hypertension.”

• A group led by Dr. Laser from the Heart and Diabetes Center NRW (HDZ NRW), Bad Oeynhausen, Germany, will report on the first use of the prototype VMS-3DE™ software, which analyses 3D ultrasound cardiac images.

• A group led by Dr. Soriano from the Seattle Children’s Hospital will report on their early experiences with the VMS in a number of children with a broad range of heart.

• VPTDF has been upgrading VMS systems to the new mobile VMS-Angelo™ model and installing new systems for customer evaluation. By the end of this quarter, there will be seven systems in clinical use, four of which are being placed for a 30-day trial period prior to purchase. Additionally, four institution-sponsored clinical research studies have been completed and favorable purchase terms are being negotiated. The company anticipates several sales agreements in the next quarter and has a number of new cardiac centers requesting a VMS-Angelo system for evaluation.

In regards to its private placement, VPTDF has issued an aggregate of 500 units for gross proceeds of $500,000. The company intends to use the proceeds from private placement for product and service commercialization of the VMS machines; clinical validation of VMS functionality, including applications for additional diagnoses and heart diseases; and for general working capital purposes and to repay debt and outstanding payables.

The company also said it has received approval from the Exchange and has issued 694,425 Common Shares at $0.099 per Common Share in payment of $68,748.09 of accrued interest owing to a holder of a debenture of the Company.

For more information, visit www.ventripoint.com

Advaxis, Inc. (ADXS) Applies for Orphan Drug Designation to Benefit from Government Incentives

Advaxis, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, this morning announced that it has submitted an Application for Orphan Drug Designation with the FDA for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer.

Orphan Drug Designation is reserved for drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the United States. The Orphan Drug Designation program entitles the sponsor to clinical protocol assistance with the FDA, as well as federal grants, tax credits, and potentially a seven year market exclusivity period.

“The U.S. Centers for Disease Control and Prevention estimates that 85% of the 7,060 new cases of anal cancer projected for 2013 are caused by HPV. The incidence of anal cancer has increased more than twofold from 1975-2009 and is rising,” stated Dr. Robert Petit, Chief Scientific Officer of Advaxis. “Despite treatment with surgery, chemotherapy, and radiation, the 5 year survival for patients with lymph node or distant metastases is less than 50%. We hope that ADXS-HPV will improve survival for patients with HPV-associated anal cancer.”

“If granted, Orphan Drug Designation for our lead drug candidate, ADXS-HPV, would provide seven years of market exclusivity for ADXS-HPV, if it is approved by the FDA, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and waiver of the $1.9 million regulatory application filing fee,” added Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis. “We are looking forward to initial data from our Brown University Study in anal cancer that is currently underway.”

For more information, visit www.advaxis.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Investment Contrarians
(DIGA)

2.

Penny Stocks Profile
(DTOR)

3.

SmarTrend Newsletters
(KEYN)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251